A natural retinoid all-trans retinoic acid (ATRA) regulates a variety of important cellular functions via retinoic acid receptor (RAR). ATRA has therapeutically been used against various malignancies including acute promyelocytic leukemia. Recently ATRA has also been recognized to be beneficial against atherosclerotic vascular disorders. However, its effects on angiogenesis remain controversial. We therefore examined ATRA effects on in vitro angiogenesis in terms of capillary-like tube formation using human umbilical vein endothelial cells ( 
naling pathways via their membrane receptors (10) . Angiogenesis is physiologically important in normal growth, development, wound healing, and reproduction, whereas pathological angiogenesis contributes to tumor growth, exacerbation of diabetic retinopathy, and various inflammations (9) . Therefore, inhibitory therapy for angiogenesis has been developed as a novel therapeutic strategy for these diseases (11) . On the other hand, it has recently been shown that stimulatory therapy for angiogenesis is effective in ischemic vascular disorders as well as ischemic heart disease by inducing formation of collaterals (12, 13) .
Several studies have shown that ATRA and its derivates modulate angiogenesis (14 -24) . However, because these results are controversial, effects and mechanisms of ATRA on angiogenesis still remain unclear. We therefore examined ATRA effects on angiogenesis using a novel tube formation assay system in which human umbilical vein ECs (HUVECs) and normal human dermal fibroblasts (NHDFs) are cocultured (25) (26) (27) . Interestingly, ATRA was demonstrated to stimulate capillary-like tube formation dose dependently, most likely due to stimulation of HUVEC proliferation and enhancement of endogenous VEGF signaling.
Materials and Methods Materials
ATRA and Am80 (1, 28, 29) were purchased from Sigma-Aldrich (St. Louis, MO) or Wako (Osaka, Japan), respectively. CD437 (30) was purchased from Tocris (Ellisville, MO). 9-cis retinoic acid (RA) and 13-cis RA (1, 31) were also purchased from Sigma-Aldrich. LE540 and LE135 were synthesized as previously described (1, 29) . Each retinoid was dissolved in ethanol at 1 mm and stored at Ϫ80 or Ϫ20 C, respectively. These stocks were diluted with the media to the desired concentrations immediately before each experiment, keeping the final concentration of ethanol at 0.1%. All experiments were performed under low-light conditions to minimize retinoid photoisomerization. Antihuman VEGF antibody (raised against Sf21-derived recombinant human VEGF containing 165 amino acid residues), antihuman VEGF receptor (VEGFR)-1 (Flt-1) antibody, antihuman VEGFR-2 (KDR) antibody, antihuman HGF antibody, and normal goat IgG were all purchased from R&D Systems (Minneapolis, MN). N-nitro-l-arginine methyl ester was purchased from Sigma-Aldrich. Bright-Glo luciferase assay system and pGL3-basic vector were purchased from Promega (Madison, WI). Lipofectamine LTX reagent was purchased from Invitrogen (Carlsbad, CA).
Cell lines and culture
HUVECs and NHDFs purchased from Kurabo (Osaka, Japan) were cultured in HuMedia-EG2 media (Kurabo) or the media provided from the angiogenesis kit (Kurabo).
Tube formation assay
Capillary-like tube formation was assessed using the angiogenesis kit (Kurabo) (25) (26) (27) according to the manufacturer's instructions. Briefly, HUVECs cocultured with NHDF onto 24-well plate were incubated either without or with ATRA (and/or other reagents or antisera) at appropriate concentrations for 4, 7, or 9 d (media replacement was performed at d 1, 4, and 7). The cells were thereafter fixed with 70% cold ethanol, incubated with mouse antihuman CD31 antibody followed by incubation with an alkaline phosphatase conjugate goat antimouse antibody, and then stained with 5-bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium to visualize tube network at d 1, 4, 7, or 9, respectively. In each assay, randomly selected five fields of view in each well were captured by digital camera under the light microscopy on ϫ40 magnification. The analysis of tube formation was then carried out by measuring total area and length of tubes per well using analytical software.
Proliferation assay
The cell numbers were counted using the CellTiter 96*AQueous One solution cell proliferation assay (Promega) according to the manufacturer's instructions. Briefly, HUVECs (3 ϫ 10 3 cells/well) seeded in 96-well plates were incubated in 200 l regular media for 24 h. The cells were then refed with media containing appropriate concentrations of ATRA or Am80, which were replaced once on d 4. On d 7, 40 l of assay reagent were added onto each well, and the plates were incubated for 90 min at 37 C, 5% CO 2 . Generation of colored formazan product, which was bioreduced from tetrazolium compound by metabolically active cells, was assessed optically by measuring the absorbance at 490 nm using a microplate reader. The background absorbance of media alone was subtracted from these data.
Migration assay
Migration of HUVECs was assessed using 3-m pore size BD Falcon HTS FluoroBlok 24-multiwell insert system (Becton Dickinson, Franklin Lakes, NJ). HUVECs (4 -5 ϫ 10 4 cells/well) were plated on the top of the insert suspended in 400 l media per well containing ATRA at appropriate concentrations without fetal bovine serum (FBS). Thereafter, 1.2 ml of media containing 5% FBS were added to each of the bottom well as a chemoattractant. The plate was incubated for 22 h at 37 C, 5% CO 2 . After incubation, cells that migrated through the membrane were labeled with Calcein-AM (Dojindo, Kumamoto, Japan) and quantitated using a fluorescent plate reader.
RNA isolation/RT-PCR
HUVECs or NHDFs grown to 50% confluence were incubated either without or with ATRA or Am80 at appropriate concentrations for 3 d. The cells were then lysed and their total RNAs were isolated using RNeasy mini kit (QIAGEN, Hilden, Germany) according to the manufacture's instructions. Total RNAs from the angiogenesis kit (HUVEC/ NHDF coculture) incubated either without or with ATRA or Am80 at appropriate concentrations were also extracted at appropriate date. Samples were treated with DNase before the experiments to remove any contaminant DNA. RT-PCR was performed using RNA PCR kit (AMV) (version 3.0; TaKaRa Bio, Otsu, Japan). Briefly, total RNAs were converted to cDNA at 50 C for 30 min with reverse transcriptase and oligo-dT primer. Reverse transcription mixtures were subjected to PCR with specific primers either for human RAR␣ (a forward primer: 5Ј-ATGGCCAGCAACAGCAGCTCCTGCCCGAC-3Ј; a reverse primer: 5Ј-CAGCCCCGTCTCCGCATCAT-3Ј) (32) , RAR␤ (a forward primer: 5Ј-TCGGGGCTGGGAAAAAGACC-3Ј a reverse primer: 5Ј-GCTAGGAC-TGTGCTCTGCTG-3Ј) (32) , or RAR␥ (a forward primer: 5-CAGGGGA-CTCTCACACCGCA-3Ј a reverse primer: 5Ј-GCAGATGAGGCAGAT-GGCGC-3Ј) (32) . PCR assays were performed in a GeneAmp PCR system 2700 (Applied Biosystems, Foster City, CA). Reactions were incubated at 94 C for 2 min and then were amplified using temperature parameters of 94 C for 30 sec; 60 C for 30 sec; and 72 C for 30 sec. Amplifications were carried out for 35 cycles, followed by a 7-min extension at 72 C. The products were separated by 1.5% agarose gel electrophoresis staining with 1 g/ml ethidium bromide and visualized with a UV transilluminator.
Real-time RT-PCR
Real-time RT-PCR was performed using LightCycler technology (Roche Diagnostics, Basel, Switzerland). Commercially designed standards and oligonucleotide primers (Search-LC, Heidelberg, Germany) optimized for the real-time LightCycler equipment were used for measurement of mRNA encoding VEGF (accession no. NM_003376), VEGFR-2/KDR (accession no. NM_002253), HGF (accession no. and 2 l of primers with optimal concentration of MgCl 2 in H 2 O. After an initial denaturation step at 95 C for 10 min, PCR cycling conditions were set as follows: denaturation at 95 C for 10 sec, annealing at 68 C for 10 sec, and extension at 72 C for 16 sec for 40 cycles. After amplification, a melting-curve analysis was performed from 58 to 95 C with a heating rate of 0.1 C/sec and a continuous fluorescence acquisition. The signals of the samples of interest were then quantified from the standard curve, and all obtained data were normalized by ␤-actin. To confirm amplification specificity, the PCR products from each primer pair were subjected to a melting curve analysis. 
ELISA
Supernatants of the HUVEC/NHDF coculture (the angiogenesis kit) incubated either without or with ATRA or Am80 at appropriate concentrations were obtained on d 1, 4, 7, or 9, respectively. In monoculture of HUVECs or NHDFs, supernatants were also obtained after 3 d incubation either without or with ATRA or Am80 at appropriate concentrations, respectively. The supernatants were thereafter analyzed for the measurement of human VEGF (Amersham Biosciences, Piscataway, NJ), b-FGF (Biosource, Camarillo, CA), HGF (R&D Systems), and Ang-1 and -2 (R&D Systems) concentrations using each ELISA kit according to the manufacturer's instructions.
Plasmid
A chimeric construct containing Ϫ1180 to ϩ338 of the human VEGF gene fused upstream of pGL3 plasmid (Ϫ1180Luc) (33, 34) was used for transient transfection studies.
Luciferase reporter gene assay
When NHDFs became 80% confluent, transient transfection studies using Lipofectamine LTX reagent were performed according to the manufacturer's instructions. Briefly, 1.0 g of reporter plasmid [either Ϫ1180Luc containing human VEGF gene promoter (33, 34) or pGL3-basic] and 0.5 g of ␤-galactosidase control plasmid in pCMV (CLONTECH, Palo Alto, CA) were transfected per 3.5-cm plate. In some experiments, 1.0 g of human RAR (-␣, -␤, or -␥) expression plasmid subcloned in pSG5 (Stratagene, La Jolla, CA) was cotransfected. Twelve hours after the transfection, the cells were replaced with new media without or with ATRA (1 m) and were incubated for an additional 24 h. After harvesting, the cell extracts were analyzed for both luciferase and ␤-galactosidase activities as previously described (35) . Transfection efficiency was normalized by the ␤-galactosidase expression.
Statistical analysis
All data are presented as mean Ϯ sem. Statistical analyses were performed with ANOVA followed by post hoc Tukey test. P Ͻ 0.05 was considered statistically significant.
Results

ATRA induces capillary-like tube formation dose dependently in the coculture system
We first investigated the effects of ATRA on endothelial tube formation. As a method for detecting tube network, we used a novel tube formation assay system in which HUVECs and NHDFs are cocultured (the angiogenesis kit) (25) (26) (27) . As shown in Fig. 1, A and B, ATRA significantly induced capillary-like tube formation in a dose-dependent manner. Coincubation with NOS inhibitor N-nitro-l-arginine methyl ester did not affect the ATRA-induced capillary-like tube formation (data not shown), suggesting little involvement of NO in the tube formation. Induction of capillary-like tube formation was also observed by incubation either with RAR␣/␤ agonist Am80 (1, 28, 29) (Fig. 1C) or RAR␥ agonist CD437 (30) (Fig. 1D) . Additionally, 9-cis RA (Fig. 1E ) as well as 13-cis RA (Fig. 1F) , both of which are intracellular products of ATRA isomerization (22, 31) , also induced capillary-like tube formation. Moreover, the ATRA-induced tube formation was inhibited by coincubation with either RAR panantagonist LE540 (29) (Fig. 1G) or RAR␤ (and ␣) antagonist LE135 (29) (Fig. 1H ). In the HUVEC/NHDF coculture on d 4, mRNA expression of all three RAR isoforms (-␣, -␤, and -␥) was confirmed by RT-PCR (Fig. 1I) . Interestingly, ATRA (1 m) treatment strongly enhanced RAR␤ expression without affecting expression of other isoforms. mRNA expression of all three RAR isoforms was also confirmed in HUVECs (Fig. 1I) . In NHDFs, although RAR␤ mRNA expression was barely detected in contrast to other isoforms, ATRA (1 m) treatment dramatically increased its expression (Fig. 1I) . Taken together, the ATRA-induced capillary-like tube formation was most likely mediated via RAR. 
ATRA induces proliferation but not migration of HUVECs
To examine the effects of ATRA on cell proliferation, we counted HUVEC number after incubation with various concentrations of ATRA for 6 d. As shown in Fig. 2A , ATRA increased HUVEC number dose dependently, suggesting the stimulatory effect of ATRA on HUVEC proliferation. The stimulatory effect was most likely mediated via RAR because Am80 also induced HUVEC proliferation (Fig. 2B) . We next examined the effects of ATRA on migration of HUVECs. As shown in Fig. 2C , migration of HUVECs was not affected by ATRA treatment in contrast to proliferation, indicating little involvement of ATRA on HUVEC migration.
The ATRA-induced capillary-like tube formation is dependent on endogenous VEGF, possibly from NHDF
Because VEGF is well known to play a central role in angiogenesis (36), we next examined the involvement of endogenous VEGF in the ATRA-induced capillary-like tube formation. When VEGF neutralizing antibody (antihuman VEGF antibody) was coincubated with ATRA, the ATRAinduced tube formation on d 9 was completely inhibited (Fig.  3, A and B) . The inhibition of the tube formation by the VEGF neutralizing antibody was specific because coincubation with normal goat IgG did not affect the tube formation (data not shown). These results suggest that endogenous VEGF is mainly involved in the ATRA-induced capillary-like tube formation.
We next examined the effects of ATRA on endogenous VEGF production. As shown in Fig. 3C , ATRA induced VEGF secretion dose dependently at d 4, 7, and 9, which was significantly higher than VEGF secretion at d 1, by measuring supernatants of the angiogenesis kit (HUVEC/NHDF coculture) by ELISA. Real-time PCR also demonstrated a significant increase of VEGF mRNA expression by ATRA (1 m) in the HUVEC/NHDF coculture at d 7 (Fig. 3D ). To examine cell types (HUVEC and/or NHDF) in which VEGF secretion was induced by ATRA, we next examined VEGF secretion per mRNA expression of respective monoculture by ELISA and real-time PCR. As shown in Fig. 3E , ATRA induced endogenous VEGF secretion dose dependently from NHDFs. ATRA was also confirmed to induce VEGF mRNA expression dose dependently in NHDFs by real-time PCR (Fig. 3F) , indicating that the ATRA effects were mediated at VEGF mRNA level. In contrast to NHDF, relatively small amounts of VEGF mRNA expression was observed in HUVECs (Fig.  3G) . Additionally, HUVEC was not observed to secrete VEGF in their monoculture supernatants in either the presence or absence of ATRA (data not shown). These data indicate that VEGF induced by ATRA in the coculture may mainly be derived from NHDF.
The effects of Am80 on endogenous VEGF production were next examined. As shown in Fig. 3H , Am80 also induced VEGF secretion dose dependently in the coculture at d 4, 7, and 9. Moreover, dose-dependent induction of VEGF mRNA expression by Am80 was observed in the coculture at d 4 (Fig. 3I) . In NHDF monoculture, Am80 was confirmed to induce VEGF secretion (Fig. 3J) as well as mRNA expression (Fig. 3K ) dose dependently. Although Am80 induced small amounts of VEGF mRNA expression in HUVECs (Fig. 3L) , VEGF secretion was not detected in the supernatants of HUVEC monoculture in either the presence or absence of Am80 (data not shown). Taken together, RAR may be involved in the ATRA-induced VEGF secretion/mRNA expression in NHDF.
We next examined the effects of ATRA on VEGF gene transcription. As shown in Fig. 3M , ATRA significantly induced VEGF gene transcription (line 4), which was significantly enhanced by RAR␣ overexpression (line 6). Moreover, overexpression of either RAR␤ or -␥ significantly augmented both basal (lines 7 and 9) as well as ATRA-induced (lines 8 and 10) VEGF gene transcription. These data thus indicate that the effects of ATRA on VEGF mRNA expression in NHDF may be mediated at gene transcription level via RAR activation.
ATRA induces VEGFR-2/KDR expression
To examine VEGF signaling pathway(s) involved in the ATRA-induced capillary-like tube formation, coincubation with VEGFR neutralizing antibodies was next performed. When VEGFR-2/KDR neutralizing antibody (antihuman VEGFR-2/KDR antibody) was coincubated with ATRA, the ATRA-induced tube formation on d 9 was completely inhibited (Fig. 4A) . In contrast, coincubation with VEGFR-1/ Flt-1 neutralizing antibody (antihuman VEGFR-1/Flt-1 antibody) did not affect the ATRA-induced tube formation (Fig.  4B) . Taken together, the ATRA-induced capillary-like tube formation is mediated via VEGF-VDGFR-2/KDR signaling. We next examined the effects of ATRA on VDGFR-2/KDR expression in HUVECs by real-time PCR. As shown in Fig.  4C , ATRA (100 nm and 1 m) significantly induced VDGFR-2/KDR mRNA expression. It is therefore indicated that upregulation of VDGFR-2/KDR in HUVECs may also be involved in the ATRA-induced capillary-like tube formation.
ATRA induces endogenous HGF and Ang-2 secretion
We next examined the effects of ATRA on angiogenic factors other than VEGF including HGF, b-FGF, and Ang-1 and -2. As shown in Fig. 5A , ATRA (1 m) significantly induced HGF secretion at d 4 and 7 by measuring supernatants of the HUVEC/NHDF coculture by ELISA. However, HGF was not detected in the supernatants obtained from either HUVEC or NHDF monoculture (data not shown). Moreover, HGF mRNA expression level was observed to be extremely low either in HUVEC or NHDF monoculture by real-time PCR (data not shown). These data indicate that coexistence of both cell types is necessary for HGF secretion by ATRA. Coincubation with HGF neutralizing antibody (antihuman HGF antibody) partially inhibited the ATRAinduced capillary-like tube formation (Fig. 5B) , indicating the involvement of HGF in the tube formation. Regarding b-FGF, although its mRNA expression as well as induction by ATRA was observed in the HUVEC/NHDF coculture at d 4 ( Fig.  5C ) as well in NHDFs (Fig. 5D) or HUVECs (Fig. 5E ) monoculture, it was not detected in the supernatants of the coculture as well as HUVEC or NHDF monoculture (data not shown). These data therefore suggest little involvement of b-FGF in the tube formation. Although Ang-1 was detected in the supernatants obtained either from the HUVEC/NHDF coculture or NHDF monoculture, ATRA was not observed to induce its secretion (data not shown). To the contrary, Ang-2 secretion was significantly induced by ATRA at d 7 (10 nm and 100 nm) and 9 (1, 10, and 100 nm) in the HUVEC/NHDF coculture (Fig. 5F) . Real-time PCR demonstrated ATRA-induced increase of Ang-2 mRNA expression in the coculture at d 4 (Fig. 5G) . In NHDF monoculture, Ang-2 mRNA expression and secretion was extremely low (data not shown). In contrast, Ang-2 mRNA expression was abundantly observed in HUVEC monoculture (Fig. 5H) . Moreover, ATRA also induced Ang-2 secretion in HUVEC monoculture (data not shown). Taken together, not only VEGF but also HGF and Ang-2 may be partially involved in the ATRA-induced capillary-like tube formation.
Discussion
In the present study, we have demonstrated stimulatory effects of ATRA on angiogenesis in terms of capillary-like tube formation. Several studies have been reported regarding ATRA effects on angiogenesis (14 -24), although obtained results are controversial. Using in vivo chicken chorioallantoic membrane assay, some reports have demonstrated antiangiogeneic effects of ATRA (14, 15, 23) , whereas proangiogeneic effects of ATRA have also been reported (22, 24) . Inhibitory effects of ATRA on angiogenesis have been reported by in vivo tumor cell-induced angiogenesis assay (16) , in vivo corneal neovascularization assay (18, 19) , and microvessel density measurement of acute promyelocytic leukemia bone marrow biopsy specimens (21) , whereas its stimulatory effects on angiogenesis have been reported by in vivo Matrigel angiogenesis assay (22) . Although antiangiogeneic effects of ATRA have been reported by in vitro three-dimensional collagen gel assay using adrenal cortex-derived bovine microvascular EC (17) , stimulatory effects of ATRA on angiogenesis have also been reported by in vitro three-dimensional fibrin matrix assay using human foreskin microvascular EC (20) and in vitro Matrigel assay using bovine aortic ECs (22) .
Discrepancies among these studies may be due to differences of methodology, experimental conditions, and ATRA concentrations used. Because angiogenesis is a complicated phenomenon with multiple processes ranging from physiological state to pathological state, selection of appropriate angiogenesis assay system is important for examination (37, 38) . Recently a novel tube formation assay system in which HUVECs and NHDFs are cocultured under relatively physiological environment (25) (26) (27) has been developed. In this assay, HUVECs produce endothelial tubes containing lumen with the aid of NHDFs secreting necessary matrix component, and the morphology of formed tubes appears heterogeneous and closely resembles capillary bed in vivo (25) (26) (27) 38) . We therefore examined the effects of ATRA on capillarylike tube formation using this assay system to obtain novel insights regarding ATRA effects on angiogenesis. Interestingly, ATRA as well as RAR␣/␤ agonist Am80 (1, 28, 29) significantly induced capillary-like tube formation. Moreover, RAR␥ agonist CD437 (30) also induced the tube formation. Involvement of RAR in the ATRA-induced tube formation was additionally confirmed by its inhibition by RAR panantagonist LE540 (29) and RAR␤ (and -␣) antagonist LE135 (29) . Because ATRA has been reported to be necessary in EC maturation as well as in capillary plexus remodeling during vascular development (39, 40) , ATRA may play important roles in both vasculogenesis and angiogenesis.
To examine the mechanism(s) of the ATRA-induced capillary-like tube formation, we first studied the effects of ATRA on HUVEC proliferation/migration. Although HUVEC migration was not affected by ATRA treatment, we could observe dose-dependent ATRA-induced HUVEC proliferation in contrast to previous studies that demonstrated little effects of ATRA on HUVEC proliferation (18, 41) . Moreover, dose-dependent induction of HUVEC proliferation was also demonstrated by Am80 treatment, indicating the involvement of RAR in the HUVEC proliferation. One reason for the observed discrepancies with our and their studies may be due to difference of used HUVECs because we obtained HUVECs identical with those used in the angiogenesis kit (HUVEC/NHDF coculture) and cultured them in the media provided from the angiogenesis kit to adjust experimental conditions with the tube formation assay. Moreover, difference of used cell passage may have affected proliferation potency and/or sensitivity to ATRA because we used HUVECs at passage 2 in contrast to previous study in which HUVEC at passage 5 were used (18) . Proliferation of HUVEC induced by ATRA via RAR may be involved in the ATRAinduced capillary-like tube formation.
Because VEGF is well known as a key regulator of angiogenesis (10, 36), we next examined its involvement in the ATRA-induced capillary-like tube formation. Our studies using VEGF-and VEGFR-neutralizing antibodies demonstrated dominant involvement of endogenous VEGF via VEGFR-2/KDR in the ATRA-induced tube formation. Moreover, we observed dose-dependent induction of VEGF secretion in the HUVEC/NHDF coculture as well as VEGF secretion/mRNA expression in NHDF by ATRA as well as Am80. ATRA has been reported to stimulate VEGF secretion in VSMCs (42) and induce VEGF gene expression in retinoblastoma cells (34) , bronchioloalveolar carcinoma cells (43) , and retinal pigment epithelial cells (44) , whereas inhibition of VEGF expression by ATRA has also been reported in neutrophil-like cells (45) . Our study thus first demonstrated stimulatory effects of ATRA on VEGF secretion/mRNA expression in fibroblasts. Additionally, we have first demonstrated stimulatory effects of ATRA on VEGF gene transcription in fibroblasts via RAR activation. Moreover, we also have first demonstrated stimulatory effects of ATRA on VEGFR-2/KDR mRNA expression in vascular ECs. It is therefore speculated that VEGF induced by ATRA in fibroblasts demonstrates paracrine effects on vascular ECs through activating its VEGFR-2/KDR that is also induced by ATRA. The enhancement of endogenous VEGF signaling by ATRA may play an important role in the ATRA-induced capillary-like tube formation.
We also examined effects of ATRA on other angiogenic factors including HGF, b-FGF, and Ang-1 and -2 (10). Interestingly, high-dose ATRA significantly induced HGF secretion in the HUVEC/NHDF coculture by d 7. Moreover, our study using HGF-neutralizing antibody indicated partial involvement of endogenous HGF in the ATRA-induced tube formation. Because HGF has recently been reported to enhance VEGF-induced angiogenesis (46) , ATRA-induced HGF and VEGF may cooperate to stimulate capillary-like tube formation. b-FGF may not be involved in the ATRAinduced tube formation because it was not detected in the supernatants of the HUVEC/NHDF coculture as well as HUVEC or NHDF monoculture, although its mRNA expression was detected in these cells. The reasons for this discrepancy are further needed to be elucidated. Additionally, although Ang-1 secretion was not induced by ATRA in the HUVEC/NHDF coculture, ATRA induced Ang-2 secretion at relatively low doses later than d 7. Because Ang-2 has recently been reported to be proangiogeneic in the presence of VEGF (47), ATRA-induced Ang-2 may have promoted capillary-like tube formation with the aid of endogenous VEGF.
Beneficial effects of ATRA on cardiovascular disorders have recently been focused (5-8, 48 -50) . ATRA has been reported to induce differentiation and inhibit proliferation, cell migration, inflammation, and extracellular matrix synthesis of VSMCs as well as suppress neointima formation and restenosis after balloon injury (5-7). ATRA has also been reported to attenuate ventricular remodeling after myocardial infarction (48) . Moreover, we recently demonstrated stimulatory effects of ATRA on NO production/eNOS phosphorylation in vascular ECs (8) that may be beneficial against endothelial damages. Additionally, RAR␣/␤ agonist Am80 (1, 28, 29) has been reported to prevent in-stent neointima formation (49) , suppress macrophage foam cell formation, and prevent atherogenesis (50) . Therefore, retinoids can be potential candidates for the treatment of atherosclerotic vascular disorders as well as ischemic heart disease. Recently therapeutic angiogenesis for the promotion of endogenous collateral vessels development has been focused in lowerlimb ischemia as well as ischemic coronary disease (12, 13) . Because we have demonstrated stimulatory effects of ATRA and Am80 on angiogenesis, retinoids may possibly be beneficial for atherosclerotic vascular disorders complicated with ischemic vascular lesions. Further studies are needed to elucidate efficacy of retinoids on ischemic vascular disorders.
In conclusion, we here have demonstrated stimulatory effects of ATRA on angiogenesis in terms of capillary-like tube formation. ATRA may have induced angiogenesis via RAR mainly by stimulation of HUVEC proliferation and enhancement of endogenous VEGF signaling and in part by induction of HGF and Ang-2 production. Retinoids may therefore be potential candidates for therapeutic angiogenesis against ischemic vascular disorders.
